Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has announced that its Phase III clinical trial, featuring the combination of toripalimab and bevacizumab as a first-line treatment for advanced hepatocellular carcinoma, has successfully met its primary efficacy goals. The results, which could significantly impact patient survival rates, will be submitted for regulatory approval shortly. Toripalimab, a domestically produced anti-PD-1 monoclonal antibody, has been recognized with China’s top patent award and is part of a broader portfolio of global clinical studies targeting various tumor types.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
